Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical firm with a market capitalization of $119.87 billion, announced today a 2.6% increase in its quarterly cash dividend.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the December 2027 expiration. One of the key data points that goes into the price an option buyer is ...

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

We noticed this today when the trades showed up on publicly available options history that we track ... spotted 10 uncommon options trades for Gilead Sciences. This isn't normal.

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...